COMPARATIVE STUDY
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[Use of a thrombin inhibitor for treatment of deep vein thrombosis and pulmonary thromboembolism in patients with thrombophilia].

Presented herein are the results of oral administration of dabigatran etexilate for treatment and secondary prevention of lower-limb deep vein thrombosis (DVT) and pulmonary thromboembolism (PTE) in patients with established thrombophilia, studying its efficacy and safety in prolonged administration during a year as compared with warfarin. The study group included a total of fifty-seven 18-to-79-year-old patients (33 men and 24 women) with DVT and PTE, taking dabigatran etexilate. The comparison group was composed of a total of 126 patients (65 men and 61 women) with DVT and PTE, taking warfarin. Efficacy of the drugs was analysed in relation to the development of relapses thromboembolic complications, with the drugs' safety profile being evaluated in relation to the development of major and clinically significant haemorrhage. It was determined that prolonged administration of dabigatran etexilate taken at a fixed dose (150 mg twice daily) for 6-12 months in patients with DVT and PTE and with confirmed thrombophilia turned out to be effective for secondary prevention of relapsing venous thromboembolic complications and lethal outcomes, indirectly contributing to recanalization of the lower-limb venous bed, with the drug possessing a favourable profile of safety concerning the development of haemorrhagic complications as compared with warfarin and requiring no routine laboratory monitoring.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app